Business news, market intelligence, and global industry analysis.
The Latest

Zydus Cadila secures tentative approval from FDA for Brivaracetam Tablets

bySrinath
June 20, 2021
1 minute read
Total
0
Shares
0
0
0

Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) to market Brivaracetam Tablets in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.

Brivaracetam is approved for the treatment of partial-onset of seizures (epilepsy).

Zydus Cadila will manufacture the epilepsy drug at the company’s formulation manufacturing facility at the SEZ, Ahmedabad.

The Indian pharma company now has 319 approvals and has so far submitted more than 400 ANDAs since the start of the filing process in FY 2003-04.

Zydus Cadila secures tentative approval from FDA for Brivaracetam Tablets
Zydus Cadila secures tentative approval from FDA for Brivaracetam Tablets. Photo courtesy of Free-Photos from Pixabay.

Last month, Zydus Cadila had been issued final approval from the FDA to market Fluphenazine Hydrochloride Tablets 1 mg, 2.5 mg, 5 mg, and 10 mg.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Phanes Therapeutics' PT217 receives FDA orphan drug designation for neuroendocrine carcinoma
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

GSK bags Nucala FDA approval for severe eosinophilic asthma in 6-11 years age group

Nucala FDA approval : GlaxoSmithKline (GSK) has secured approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) for the treatment of severe eosinophilic asthma in children, aged six years and older. Nucala, which is a monoclonal antibody that targets IL-5, is now the only targeted biologic to be approved by the FDA […]

The post GSK bags Nucala FDA approval for severe eosinophilic asthma in 6-11 years age group appeared first on PharmaNewsDaily.com.

bypharmanewsdaily